Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “The data from our SOLSTICE Phase 2 trial suggest that tobevibart and elebsiran can rapidly reduce hepatitis delta virus to undetectable ...

Analytik Jena AG is the world’s first company to bring to the market a kit with CE-IVD certification for the molecular diagnostic quantification of hepatitis delta virus (HDV) RNA, thus reaching a ...

(Scientific Reports) The FDA granted a breakthrough therapy designation for brelovitug, a monoclonal antibody in development for chronic hepatitis delta, drugmaker Bluejay Therapeutics announced.

Vir Biotechnology has enrolled the first subject in the Phase III ECLIPSE registrational programme of tobevibart and elebsiran in individuals with chronic hepatitis delta (CHD), an inflammatory ...